MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

56.03 -0.57

Overview

Share price change

24h

Current

Min

55.31

Max

56.56

Key metrics

By Trading Economics

Income

-14M

-130M

Sales

-888K

143K

Profit margin

-90,972.727

Employees

437

EBITDA

-12M

-142M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+57.08% upside

Dividends

By Dow Jones

Next Earnings

26 Feb 2026

Market Stats

By TradingEconomics

Market Cap

1.6B

5.7B

Previous open

56.6

Previous close

56.03

News Sentiment

By Acuity

34%

66%

91 / 361 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jan 2026, 23:29 UTC

Hot Stocks

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 Jan 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 Jan 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 Jan 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 21:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 Jan 2026, 21:41 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 Jan 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 Jan 2026, 20:44 UTC

Earnings

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 Jan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 Jan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 Jan 2026, 19:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 Jan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 Jan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 Jan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 Jan 2026, 16:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 Jan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

57.08% upside

12 Months Forecast

Average 88.64 USD  57.08%

High 105 USD

Low 67 USD

Based on 12 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

91 / 361 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat